- After trading up in the premarket, shares of Oncolytics Biotech (ONCY -6.3%) have now made a rather decisive turn lower as investors and analysts digest and evaluate this morning's top-line data from a study of a Reolysin/carboplatin/paclitaxel combo in second-line platinum-refractory, taxane-naïve head and neck cancers.
- Some seem to be concerned about the absence of comprehensive OS data — the company provides OS data for 88 patients but not for the entire group (118) due to the "confounding" effect of "post-discontinuation therapy" that some patients received at certain enrolling centers.
- Other questions apparently revolve around the way the company cut the patient population (see here and here) and p-values. Here's Forbes' Matthew Herper: "ONCY says non-proportional HR causes them not to provide p-values."